Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Conditions

Arthritis, Rheumatoid 6Spondylitis, Ankylosing 2Psoriasis 2Crohn Disease 2Colitis, Ulcerative 2Uveal Melanoma 1Plaque Psoriasis 1Melanoma 1Hidradenitis Suppurativa 1Healthy Adult Male 1Healthy 1Acne Vulgaris 1Abscess 1

Interventions

Certolizumab Pegol 5MEDI2070 2Infliximab 2Adalimumab 2secukinumab 1golimumab 1Ustekinumab 1CT-P13 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Crohn Disease × Adalimumab × Clear all
NCT04655807 2025-04-27

DUET

Janssen Research & Development, LLC

Phase 2 Withdrawn

Crohn Disease

NCT02499783 2019-01-04

Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease

AbbVie

Phase 3 Completed
205 enrolled 39 charts

Crohn Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡